Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab + Erlotinib in First-Line MET+ EGFR-Mutant NSCLC
NCT01887886Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2013
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Onartuzumab + Erlotinib with Placebo + Erlotinib (2 arms). Primary endpoint: Progression-Free Survival. Started Dec 2013; status: completed.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01887886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887886.